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Background: Lipocalin-2 (LCN2) is widely expressed in the organism with pleiotropic roles. 
In particular its over-expression correlates with tissue stress conditions including inflammation, 
metabolic disorders, chronic diseases and cancer.  
Objectives: assess the effects of systemic LCN2 overexpression on adipose tissue and glucose 
metabolism. 
Subjects: Transgenic mouse model with systemic LCN2 overexpression (LCN2-Tg) and age/sex 
matched wild type control mice.  
Methods: Metabolic cages and body mass parameters evaluation; adipose tissue histology and 
Real-Time PCR analysis; glucose tolerance test; cytofluorimetric, micro-PET and serum analysis.  
Results: LCN2-Tg mice were smaller compared to controls but they ate (P= 0.0156) and drank (P= 
0.0057) more. Aged LCN2-Tg mice displayed a lower body mass index (P= 0.0018) and a higher 
amount of visceral adipose tissue. Furthermore, LCN2-Tg mice with body weight ≥ 20g, showed 
adipocytes with a higher cell area (P<0.0001). LCN2-Tg also showed an altered expression of genes 
involved in adipocyte differentiation, obese phenotype and inflammation. In particular, mRNA 
levels of adipocyte-derived PPAR  (P= <0.0001), SRBF1 (P <0.0001), FBP4 (P= 0.056), TNFα 
(P= 0.0391), IL6 (P= 0.0198) and leptin (P=0.0003) were all increased. Furthermore, glucose 
tolerance test in LCN2-Tg mice showed a delay in glucose tissue uptake from blood to tissues (30 
minutes P= 0.032, 60 minutes, P= 0.0171) and micro-PET analysis demonstrated reduced whole 
body glucose consumption along with a decreased MRGlu (metabolic rate of glucose) in both 
muscle and brown adipose tissue (P= 0.0247). Nevertheless, an almost nine-fold acceleration of 
hexokinase activity was observed in LCN2-Tg mice liver compared to the controls (P= 0.0027). 
Moreover, AST and ALT (P= 0.0421; P= 0.0403) were increased confirming a liver involvement. 
Conclusions: We show that LCN2 profoundly impacts adipose tissue size and function and glucose 
metabolism indicating that LCN2 should be considered as a risk factor for metabolic disorders 





Lipocalin-2 belongs to a superfamily of more than 20 proteins identified originally in human 
neutrophil granules 1. Lipocalins bind a wide array of small hydrophobic ligands, which include 
bacterial siderophores. LCN2 is involved in innate immunity and regulates several cellular 
processes 2. It is expressed in several tissues and overexpressed during tissue stress conditions like 
postpartum uterus involution 3,4. Within the skeleton, LCN2 is expressed by chondrocytes in the 
hypertrophic cartilage of the growth plate of long bones, that undergo endochondral ossification 5, 
and by differentiating osteoblasts along with its receptor 6. 
LCN2 is widely overexpressed under pathological conditions such as liver and lung inflammation 
4,7 where macrophages and cells of the immune response produce a large amount of this protein, 
which correlates with cirrhosis-dependent liver failure 8,9. Moreover, LCN2 overexpression in the 
organism actively participates to several disorders and diseases. In bone LCN2 can unbalance, when 
overexpressed in mice, the finely tuned bone turnover and modify the bone marrow environment 10. 
In chronic kidney disease, LCN2 overexpression seems to play an active role in causing the renal 
phenotype 11. In ovarian 12 pancreatic 13 and breast cancers 14 LCN2 is an important pro-survival 
protein. 
Among the pathological conditions in humans, obesity has increased at an alarming rate in the last 
twenty years, thus becoming a major health and economic issue for industrialized countries, mainly 
due to its high number of complicating diseases 15. For this reason, clinical interest on adipose 
tissue has been rapidly developing and, thanks to recent studies, this tissue is no longer believed to 
have uniquely a lipid-storage capability but it is recognized as a diffused endocrine organ meant at 
producing hormones and cytokines 16. The latter, when found within adipocytes, are also termed 
adipokines and play a dramatic role in the modulation of the adipose tissue response, linking obesity 
to inflammation. An inflammatory state is associated with the current pandemic of obesity and it is 
an important pathogenetic factor that contributes to the increased prevalence of the so-called 
metabolic syndrome 17,18. Nowadays it is a common opinion that LCN2 is endowed with pro-
inflammatory and metabolism-disrupting properties 19. Furthermore, recent studies suggest that this 
protein is an independent risk factor for both inflammation and insulin resistance before diabetes 
onset. Overall, LCN2 is recognized as one of the adipokines playing a role in obesity and metabolic 
syndrome 20. 
Although recent studies reported a correlation between serum LCN2 concentration, glucose 
metabolism alterations and inflammatory markers 18 the underlying mechanisms remain largely 
undefined. In particular, ablation of LCN2 expression has been found to only marginally improve 
obesity-associated glucose intolerance without affecting either age- or obesity-mediated insulin 
resistance 20. Moreover, a recent report suggested that bone-derived LCN2 regulates metabolism by 
suppressing appetite through MC4R in the hypothalamus, thus assigning a leading role to LCN2 in 
bone endocrine function 21. 
In this scenario a better knowledge about LCN2 effects at the organism level is crucial for our 
understanding of the pathogenesis of metabolic disorders and possibly to open up new paths for 
therapeutic approaches. 
In the present study, we took advantage of a transgenic mouse model over-expressing LCN2 under 
the control of the mouse pro alpha 1 type I collagen promoter, which was previously generated in 
our laboratory 22. In this mouse model LCN2 is overexpressed by osteoblasts and released in the 
serum and therefore this model is suitable to study LCN2 pleiotropic role in the body.   
In 18 month old LCN2-Tg mice we observed an increased expression of some relevant genes linked 
to obesity such as leptin, FBP4, TNFα and IL-6 along with an altered glucose tolerance. Moreover, 
LCN2 overexpression promoted glucose metabolism changes and was associated to a large increase 
in adipose tissue volume, body mass, food and water intake. These data point to LCN2 altered 
expression as a promoting factor for the development of metabolic disorders in ageing. 
 
MATERIAL AND METHODS 
Animal maintenance and generation of LCN2-Tg Mice 
Procedures involving the animals and their care were all performed according to the institutional 
guidelines, in compliance with national and international laws and guidelines for the use of animals 
in biomedical research. Mice were bred and maintained at the Institution’s animal facility (IRCCS 
AOU - San Martino - IST, Genova, Italia). LCN2-Tg mice were generated as previously described 
22. Briefly, the full-length cDNA coding for mouse LCN2 was cloned between the mouse pro α1 
collagen I promoter 23 and the Bovine growth hormone polyadenylation (bpA) plasmid sites. 
Pronuclei of FVB mice (Charles River) fertilized eggs were injected with this recombinant 
construct and then implanted in pseudo-pregnant foster mothers. Transgenic mice were identified 
by PCR analysis of tail genomic DNA with LCN2 cDNA and bpA specific primers. 
All analyses were performed on 18 month old mice. 
 
Metabolic analysis 
Food and water consumption were measured in 10 control Wt and 11 LCN2-Tg mice that were 
weighed and housed for 24 hours in metabolic cages. For both groups, body surface area was 
derived from the DuBois equation:  
 
 
Thereafter, body mass index (BMI) was calculated as the ratio between body weight and surface 
area (g/m2). 24. 
 
Histology 
For standard histology, visceral fat was removed, weighed, and fixed immediately in 4% buffered 
formaldehyde (Sigma Aldrich). After dehydration in a progressive series of ethanol, fat samples 
were clarified in xylene and paraffin embedded. Five µm sections were obtained and stained with 
Haematoxylin and Eosin (H&E) for histological examination. At least 10 slides for each sample 
were scored for fat histology an at least 5 tissue sections were analysed for each animal. Images 
were acquired by an Axiovert 200M (Zeiss, Germany). Adipocytes were counted in fat sections 
from Wt and LCN2-Tg mice and surface area was measured using an image analysis software 
(ImageJ, NIH USA). Each count represents the mean value of 5 different blinded fields. 
 
Adipose macrophage immune profiling 
After 8 hours of starvation mice were sacrificed and visceral fat was dissected, minced into fine 
pieces (2–6 mm3) and digested in a buffer isolation solution (PBS w/o Ca2+ Mg2+, 1.5% FBS, 
Collagenase I 1mg/ml). The homogenized suspensions were maintained in water bath at 37°C with 
intermittent shaking for 1.5 hours, then passed through a 7 µm mesh. The cells suspension with the 
was centrifuged at 400g for 10 minutes at 25°C and then washed in RPMI1640. The following 
antibodies were used to discriminate two different subsets of macrophages (MΦ): CD45 APC, 
F4/80 PeCy7, CD86 FITC for the M1 inflammatory MΦ, and the CD206 FITC for the M2 anti-
inflammatory MΦ. Due to the overlap of the specific MΦ subset markers (CD86 and CD206), after 
accurate suspension, each sample was equally divided in two separate tubes. Incubations were 
performed at saturating antibody concentrations for 30 min at 4°C. For each sample 105 cells were 
Body surface (m2) = 0.007184 X weight (Kg 0.425) X height (cm 0.725) 
run on a FACS CyAN ADP flow cytometer (Beckman-Coulter, Brea, California). Results were 
analysed with the Summit software (Beckman-Coulter). 
 
Real time PCR analysis 
Small visceral adipose tissue samples from 12 LCN2-Tg and 8 Wt 18 months old mice were 
isolated and homogenized in Qiazol reagent (Qiagen). Subsequently, samples were extracted by 
Rneasy plus mini kit (Qiagen), quantified by optical density (OD) measurement, and checked for 
quality. cDNA synthesis was performed using Omniscript Reverse Transcription Kit (Qiagen). Real 
time PCR reaction was performed using specific primers for each gene (Table 1) and Platinum 
SYBR green qPCR SuperMix-UDGwith ROX kit (Invitrogen). Detection was performed using the 
7500 fast real time PCR system (Thermo Fisher Scientific). Relative expression values with 
standard errors were obtained using the Thermo Fisher Scientific software and normalized to the 
expression of the housekeeping gene Hprt. Each sample was run in triplicate. 
 
Glucose tolerance test  
After a short fasting time (5-6 hours) 8 Wt and 9 LCN2-Tg mice were intraperitoneally injected 
with a glucose solution (1,5 mg/g). Glucose concentrations were measured before the glucose 
administration and monitored every 10 to 30 minutes for 30 minutes to 2 hours after the injection 25.  
 
micro-PET analysis 
In vivo imaging was performed according to a protocol validated in our lab 26 27 28. Daily quality 
controls always documented a radiochemical ≥ 98% purity of in house produced 18F-
fluorodeoxyglucose (FDG). 
Before PET scan, 7 Wt and 8 LCN-Tg mice were kept under fasting conditions with free access to 
water for 6 hours. Mice were weighted and anesthesia was induced by intra-peritoneal 
administration of ketamine (100mg/kg) and xylazine (10 mg/kg) (Imalgere 1000, Bio98 Srl, Milan, 
Italy, respectively). Serum glucose level was tested and animals were positioned on the bed of a 
dedicated micro-PET system, (Albira, Bruker, Billerica, MA, USA), the double-ring configuration 
of which permitted to cover the whole animal body in a single bed position. A dose of 3-4 MBq of 
FDG was then injected through a tail vein, soon after start of a list mode acquisition lasting 50 
minutes.  
The whole dataset was thus binned using the following framing rate: 10 x15 s, 5 x30 s, 2 x150 s, 
6x300 s, 1 x600 s. PET data were reconstructed using a maximal likelihood expectation 
maximization method (MLEM). An experienced observer, kept unaware of the experimental type of 
the analyzed model, identified a volume of interest (VOI) in the left ventricle. Then, the computer 
was asked to plot the time-concentration curve within this VOI throughout the whole acquisition to 
define arterial tracer input function. Whole body FDG clearance (in ml x min-1) was calculated, 
using the conventional stochastic approach, as the ratio between injected dose and integral of input 
function from 0 to infinity, fitting the last 20 minutes with a mono-exponential function 29. This 
value was thus multiplied by serum glucose level to measure whole body glucose consumption and 
then normalized based on body weight and thus expressed as µM x min-1 x 100g-1. All dynamic 
scans were processed according to the Gjedde-Patlak 30 graphical approach to compartmental 
analysis by using the routine of a dedicated software (PMOD, Zurich, Switzerland). Briefly, the 
software utilizes the input function and transforms the original tissue activity measurements by 
fitting the data in each voxel with the slope of the regression line defined by the model. In all cases, 
the lumped constant value was set at 1. Further VOIs were drawn on the obtained parametric maps 
to estimate metabolic rate of glucose (MRGlu) in brown adipose tissue (BAT) and in hind limb 
skeletal muscles (SM).  
Hepatic FDG kinetics was assessed according to a method previously validated in our lab 29. 
Briefly, the algorithm utilizes time-concentration curve in the gut to derive portal vein input 
function and provides a description of parameters quantifying phosphorylation rate (kmf) and 
dephosphorylation rate (kfm) of FDG within hepatocytes.    
   
Serum Analysis 
All animals were sacrificed after a 6 hours of fasting to allow cardiac blood samples collection. 
Samples were centrifuged for 60 minutes at 7,500×g and then stored at -80°C. In addition to 
glucose, urea, creatinine, triglycerides, total bilirubin, bile acids, AST, ALT were also assayed in 




All experiments were performed using at least 7 Wt and 7 LCN2-Tg 18 month old mice.  Data were 
expressed as mean ± SEM and analyzed using GraphPad Prism software (GraphPad Software, Inc., 
La Jolla, CA). Statistical analysis was performed by a two-tailed t-test. 
 
RESULTS 
LCN2-Tg mice weight and metabolism  
To investigate the role of LCN2 in the control of body mass, fat accumulation in the adipose tissue 
and food and water intake, we used a transgenic mouse model that overexpresses LCN2 in the 
serum 22. As previously reported 6, we found that 18 month old  LCN2-Tg displayed a smaller body 
size and weight compared to Wt controls (Fig 1A). Similarly, the body mass index (BMI) of 18 
month old mice was lower for LCN2-Tg compared to Wt (P= 0.0018) (Fig. 1B). Furthermore, 
LCN2-Tg mice showed a higher amount of fat per body weight (Fig 1C, D). To assess the levels of 
the LCN2 mRNA in the adipose tissue, we performed a real-time PCR analysis. This analysis 
showed that the LCN2 mRNA was expressed at much higher levels in the adipose tissue of LCN2-
Tg mice compared to Wt (P<0.001) (Fig 1E). Despite their lower body mass and size, LCN2-Tg 
showed a higher food (P= 0.0156) and water (P= 0.0057) intake (Fig.1F).   
 
Physiology and inflammatory status of LCN2-Tg mice visceral adipose tissue  
To better characterize the increased visceral adipose tissue, we investigated this issue at a 
histological and molecular level (Fig. 2). Necroscopy on mice confirmed a higher amount of 
visceral adipose tissue in LCN2-Tg (Fig. 2A) and related H&E staining showed no major 
leucocytes infiltration. However, this analysis revealed in the adipose tissue of LCN2-Tg with a 
body weight higher than 20g, a lower total number of adipocyte compared to Wt controls (P= 
0.0001) (Fig. 2B). Furthermore, LCN2-Tg adipocytes showed a higher degree of hypertrophy 
because we detected a larger mean cellular area (P< 0.0001) (Fig. 2C)  
From these results we hypothesized an aberrant expression of genes involved in adipocyte 
differentiation, inflammation and body weight. Therefore, we performed a real-time PCR analysis 
on adipose tissue in randomly selected Wt and LCN2-Tg mice. 
In particular, we evaluated mRNA levels for PPARγ and SRBF1, two relevant proteins expressed 
during adipocyte differentiation 31 and the mRNA levels for the FBP4 (fatty acid binding protein) 
and Leptin, which are involved in both obesity and metabolic syndrome 32. Fig. 2D and Fig. 2E 
show that these mRNAs were all up-regulated (P<0.001; P<0.001; P= 0.0056; P= 0.0003) in LCN2-
Tg adipose tissue compared to Wt.  
Since obesity often correlates with increased circulating inflammatory adipokines we studied by 
real-time PCR analysis the expression of the pro-inflammatory cytokine e.g. TNFα and IL-6 
mRNAs in the adipose tissue of randomly selected mice. This analysis revealed a significantly 
increased expression of both TNFα (P= 0.0391) and IL-6 transcripts (P= 0.0198) in LCN2-Tg mice 
(Fig. 2E) compared to controls. 
Fat resident macrophages are major players in the modulation of the inflammatory 
microenvironment within the adipose tissue 33. To assess whether higher levels of LCN2 affects the 
presence of these cells in the adipose tissue, we measured by FACS analysis the percentage of 
inflammatory M1 and anti-inflammatory M2 macrophages, identified by the expression of CD86 
and CD206, respectively. This analysis showed similar percentage of fat resident M1 and M2 
macrophages in LCN2-Tg and Wt mice (Fig. 2F) 
 
Glucose homeostasis in LCN2-Tg mice 
Given the alterations found in the LCN2-Tg mice adipose tissue, we hypothesized the presence of 
alterations in glucose homeostasis in these mice. Therefore we performed a glucose tolerance test 
(GTT), which showed no differences between the Wt and LCN2-Tg mice in term of starting and 
final values of glucose concentration (Fig. 3). However, a relative delay in glucose downward slope 
occurred in LCN2-Tg mice, with significantly higher glucose levels attained at 30 min (P= 0.032) 
and 60 min (P= 0.0171) after intraperitoneal injection.  
 
Micro-PET 
The glucose tolerance test suggested a possible slower glucose transfer from blood to tissues in 
LCN2-Tg compared to Wt mice. To test this hypothesis, we performed in vivo total body micro-
PET analysis. LCN2-Tg mice started with lower glucose serum levels (P=0.0499) (Fig. 4A). During 
micro-PET analysis their glucose disposal was reduced with respect to Wt (Fig. 4B, C). Similarly, 
transgenic mice attained lower MRGlu values both in muscle (Fig. 4D), and in brown adipose tissue 
(P= 0.0247) (Fig. 4E). Altogether, these data suggest that LCN2 overexpression significantly 
impaired tissue glucose utilization. This behaviour was not confirmed by fasting serum glucose 
level that, in fact, was lower in LCN2-Tg than in Wt. The mismatch between lower sugar utilization 
and reduced glucose availability was explained by the effect of LCN2 overexpression on liver 
metabolism which, under fasting conditions, showed an almost nine-fold acceleration of hexokinase 
activity with respect to Wt mice as documented by k mf (P= 0.0027) (Fig. 4F). Under this condition, 
LCN2-Tg liver buffer effect on serum glucose was relatively hampered by a less prominent glucose 
G6P-phosphatase dependent dephosphorylation process, which, however, did not reach statistical 
significance (Fig. 4G). 
 
Serum analysis  
Glucose homeostasis alteration and visceral adipose tissue accumulation is closely associated to 
obesity 32. This disease is characterized by dyslipidemia and a low inflammatory state that in 
humans is often associated with other serum parameter alterations. In our LCN2-Tg mice however 
total cholesterol was significantly lower (P= 0.0193) (Fig.5A), while triglyceride levels tended to be 
lower in comparison to Wt, without reaching statistical significance (Fig.5A). We could not find 
any relevant differences in serum of creatinine (Fig. 5B), bile acids (Fig. 5C), or in total bilirubin 
levels between the two mice groups (Fig. 5D). By contrast, in LCN2-Tg mice we found increased 
serum urea (P=0.0025) (Fig. 5E), aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) levels (P=0.0421) (Fig. 5F).  
 
DISCUSSION  
Lipocalin-2 is expressed in several tissues and its overexpression is linked to several pathological 
outcomes. However, the exact molecular mechanisms at the basis of the LCN2 effects in different 
tissue and organs are not clear yet. LCN2-Tg mice, which was generated in our laboratory, 
overexpressed LCN2 within blood and tissues 6, making this mouse model a good tool to 
investigate the effects of the up-regulation of LCN2 expression in the whole organism. Previous 
works from our group assessed the effects of persistent LCN2 overexpression on bone physiology at 
first 6 34. In particular we reported bone loss and bone marrow modifications, including 
hematopoietic changes. Here we show that, in aged mice, persistent LCN2 overexpression interferes 
with body weight and glucose metabolism. 
In particular, LCN2-Tg mice displayed higher amount of visceral adipose tissue and those mice 
heavier than 20g presented bigger adipocytes than controls. This phenotype is accompanied by an 
increase of the BMI. However, further studies are needed to understand the higher variability in 
body weight and BMI displayed by LCN2-Tg compared to age-matched Wt mice. Several 
evidences show that obesity is characterized by enlarged adipose tissue with increased production 
of both LCN2 and other pro-inflammatory adipokines, including TNFα, IL-6, MCP-1, and Resistin 
35 which are strongly linked to metabolic abnormalities 32. Our gene expression analysis, performed 
on adipose tissue of randomly selected LCN2-Tg mice, showed that besides the expected 
overexpression of LCN2 mRNA, the transcripts for two pro-inflammatory adipokines, TNFa and 
IL-6 are up-regulated in these mice compared to Wt.  
 
These data show that the adipose tissue in LCN2-Tg mice developed an inflammatory obese-like 
phenotype. However, as we could not detect by histology and FACS analyses neither a relevant 
infiltration by immune cells or changes in the ratio between M2 pro-inflammatory and M1 anti-
inflammatory macrophages, we hypothesize that LCN2 exerts its pro-inflammatory effects mainly 
through adipocytes. Expression analysis also revealed that, PPARγ, SRBF1, leptin and FBP4 
mRNAs were all up-regulated in LCN2-Tg adipose tissue. Leptin is a hormone, which contributes 
to energy balance regulation by inhibiting hunger 36 through its hypothalamic arcuate nucleus 
receptors 37. In obesity, a decreased sensitivity to leptin occurs 38 along with a positive correlation 
between obesity and high systemic leptin levels 39. Our data, in view of these reports, strongly 
suggests the existence of leptin resistance in Lcn2-Tg mice. In LCN2-Tg mice, indeed, both food 
and water intake are higher compared to Wt mice, despite a smaller body size was observed in the 
former. Furthermore, the increase in PPARγ, and SRBF1 mRNAs strongly suggest a high metabolic 
activity of fat tissue in LCN2-Tg as these genes are very active during adipocyte differentiation and 
up-regulated in cardiovascular and metabolic abnormalities 40 41 42. 
Obesity has effects on glucose tolerance, which is often decreased in this condition. A slightly 
improved glucose tolerance was found in high-fat diet fed mice with LCN2 deficiency without any 
differences in insulin sensitivity 20. A different study suggested that, compared to Wt mice, LCN2 
deficient animals had deleterious diet effects, including dyslipidaemia, fatty liver disease, insulin 
resistance and lower mitochondrial oxidative capacity 43. In our mice overexpressing LCN2, the 
GTT curve showed that LCN2-Tg mice took longer to transfer glucose from blood to tissues 
compared to Wt. Our micro-PET data revealed an unexpected near-nine-fold acceleration of 
hexokinase activity in LCN2-Tg with respect to Wt mice as documented by Kmf. It is well known 
that liver plays a crucial role in glucose systemic level changes 20. Therefore, micro-PET data 
together with the observed alterations in circulating liver function markers warrant further 
investigations upon hepatic involvement in LCN2-Tg mice. Interestingly, a previous study reported 
that LCN2 is a major factor leading to metabolic liver alterations 42. Moreover, before micro-PET 
analysis glucose levels were tested in LCN2-Tg mice: this revealed that in this case the starting 
point was different in Wt compared to LCN2-Tg who displayed slightly lower glucose 
concentrations. However, under vivarium conditions, glucose levels did not significantly differ 
between LCN2-Tg and Wt groups. Such discrepancy might be explained by the stress typically 
faced by the animals during transportation and before undergoing micro-PET. Should this be the 
case, however, LCN2-Tg mice could be thought to react to stress differently from Wt mice.  
It should also be taken into account that the metabolic alteration observed in LCN2-Tg may also 
due in part to the skeleton, which is an endocrine organ per se and that osteoblasts contribute to 
energy metabolism through the expression of their own endocrine signals, including osteocalcin, a 
peptide involved in insulin secretion/sensitivity and energy expenditure regulation 44. In particular, 
we previously observed in LCN2-Tg mice bone a decreased amounts of osteocalcin-related mRNA 
and this could contribute to the observed changes in glucose metabolism 6. 
In conclusion, here we show that LCN2 profoundly impacts adipose tissue size and function and 
glucose metabolism indicating that LCN2 should be considered as a risk factor for metabolic 
disorders leading to obesity. 
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Figure 1. Mice weight and metabolism. In all the experiments, N≥6 Wt and LCN2-Tg (Tg) 18 
month old  mice were analysed, unless otherwise specified. 
(A) Analysis of the weight variance in relationship to the length of the animals. (B) Analysis and 
histogram of the average of the body mass index (BMI). (C) Analysis of the variance of the weight 
of the visceral fat in relationship to the total weight of the animals (n=3). (D) Representative 
pictures that show the interspersed variability in the amount of visceral fat between Tg mice in 
relationship to the one observed in Wt mice. (E) Adipose tissue real-time PCR for LCN2 mRNA 
expression. (F) Metabolic cages analysis for food and water intake. 
Results are means  ± SEM. Data were analysed with student t-test. *  p< 0.05,  ** p< 0.01, ***p< 
0.001. 
 
Figure 2. Physiology and inflammatory status of the visceral adipose tissue. 
In all the experiments, N≥6 Wt and LCN2-Tg (Tg) 18 month old  mice were analysed, unless 
otherwise specified. (A) Top panels shows representative pictures of visceral adipose tissue in Wt 
and Tg mice with body weight <20g (Tg1) and >20g (Tg2); bottom panels show correspondent 
representative pictures of Hematoxilin Eosin (H&E) staining of the visceral adipose tissue. (B) 
Adipocytes number per area in H&E of Wt and Tg mice <20g and >20g of weight. (C) Adipocyte 
area expressed in m2 of LCN2-Tg mice with body weight <20g and >20g. (D) Adipose tissue real-
time PCR analysis for PPARγ and SRBF1. Y-axis represents the mRNA fold increases of each gene 
versus Wt. (E) Adipose tissue Real-time PCR analysis for FBP4, Leptin, TNFα and IL-6. Y-axis 
represents the mRNA fold increases of each gene versus Wt. (F) FACS analyses for fat resident 
macrophages (MΦ) subpopulations percentage.  
Results are means ± SEM. *p< 0.05,  **p< 0.01, ***p< 0.001, ****p< 0.0001. 
 
 Figure 3: Glucose tolerance test  (GTT). 
N≥6 Wt and LCN2-Tg (Tg) 18 month old  mice were starved for 8 hours and challenged with 
glucose (1,5 mg/g) by intraperitoneal injection. Glucose concentrations were monitored at Time 0 
and at different time points after the glucose intraperitoneal injection. Results are means ± SEM. 
*p< 0.05. 
 
Figure 4: Micro-PET analysis. N≥6 Wt and LCN2-Tg (Tg) 18 month old  mice were studied twice 
in random sequence. (A) Blood glucose concentrations before micro-PET analysis. (B) FDG 
detection by radiographic image in whole body. Arrows indicate brown fat FDG disposal in Wt and 
Tg mice. Fat glucose metabolic rate (MRGlu) in Whole body (C), muscle (D), and brown adipose 
tissue (E). Phosphorilation (kmf) (F) and dephosphorilation (G) rate (kfm) of FDG in hepatocytes. 
Results are means ± SEM. *p< 0.05. 
 
 Figure 5: Serum analysis. N≥6 Wt and LCN2-Tg (Tg) 18 month old  mice were sacrificed and 
cardiac blood samples collected. Histograms of the amount of circulating: total cholesterol and 
triglycerides (A), creatinine (B), biliary acids (C), total bilirubin (D), urea (E) and aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels (F). 
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